996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

  • Radioconjugates: Targeting for Precision Suzanne Elvidge
    May 06, 2025
    The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
  • Now and Next in Type 2 Diabetes Suzanne Elvidge
    May 06, 2025
    Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
  • Oncolytic viruses in cancer treatment Suzanne Elvidge
    April 21, 2025
    Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
  • Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes Suzanne Elvidge
    April 01, 2025
    Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
  • Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards Suzanne Elvidge
    March 31, 2025
    In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.
  • Moving Forward in Translational Models Suzanne Elvidge
    March 03, 2025
    Translational medicine aims to bridge the gap between basic and clinical science. New translational models help predict drug efficacy and safety, but need collaboration.
  • Working in Rare Diseases: A Business Model Suzanne Elvidge
    February 28, 2025
    Rare diseases, by definition, affect a small population.
  • The Role of Biosimilars Suzanne Elvidge
    February 12, 2025
    Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
  • The Value of Streamlining Manufacturing Suzanne Elvidge
    February 12, 2025
    Drug manufacturing makes up a significant part of what it costs to develop drugs. As expenditures for ingredients, power, equipment, rent and staff increase, companies are working hard to find ways to cut outlays through streamlining.
  • Making Sense of Antisense: The Power of Gene Silencing Suzanne Elvidge
    February 11, 2025
    This article explores antisense oligonucleotides (ASOs) in gene silencing, covering their mechanism, development, applications, pros and cons, and future delivery challenges.
PharmaSources Customer Service